Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Primary Myelofibrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering.
The 7 major primary myelofibrosis markets are expected to exhibit a CAGR of 3.07% during 2023-2034.
This report provides an exhaustive analysis of the primary myelofibrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc.
The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary myelofibrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report.
Market Highlights
- The increasing cases of gene mutations, which affect the signaling networks involved in the regulation of blood cell production and cause abnormal cell growth, are primarily driving the primary myelofibrosis market.
- In addition to this, the escalating incidence of chronic inflammation and immune dysregulation that may contribute to the fibrosis and disruption of healthy tissues is also creating a positive outlook for the market.
- Moreover, the widespread adoption of targeted therapies, like Janus kinase (JAK) inhibitors, on account of their numerous advantages, such as reducing symptoms, controlling spleen enlargement, and improving quality of life in patients, is further bolstering the market growth.
- Apart from this, the rising application of stem cell transplantation, since it aims to eradicate the abnormal clone of stem cells responsible for the formation of fibrous tissues in the bone marrow, is acting as another significant growth-inducing factor.
- Additionally, the emerging popularity of immunomodulatory drugs, including thalidomide and lenalidomide, which help to restore immune balance by modulating the release of certain cytokines, is expected to drive the primary myelofibrosis market during the forecast period.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the primary myelofibrosis market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the primary myelofibrosis market
Competitive Landscape
This report also provides a detailed analysis of the current primary myelofibrosis marketed drugs and late-stage pipeline drugs.
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
For more information about this report visit https://www.researchandmarkets.com/r/env183
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
